CYP2C9 and Hypertension: To assess the antihypertensive effect of losartan therapy in individuals with different CYP2C9 genotypes, we used a previously developed cardiorenal model (Kutumova et al., 2022; Kutumova et al., 2021), which, in particular, reproduces the pharmacological action of losartan, and examined 100 virtual patients with arterial hypertension generated for it earlier (Kutumova et al., 2022).